An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer

Ineveld, BM van; Hout, BA Van; Rutten, Ffh

doi:10.1097/00001813-199903000-00005

Cited by 13 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, a study that analysed the patients' preferences with respect to the toxicity profile and the ease of administration showed that 91% of patients preferred raltitrexed to other 5FU-based regimens, such as those advocated by The Mayo Clinic, Gramont or Lokich (Young et al, 1999). Furthermore, a study analysing the treatment-related costs concluded that, although raltitrexed treatment-related costs were high, they were compensated for when savings attributable to its ease of administration were considered (Groener et al, 1999). Of greater concern, however, are the results of a study that compared the Lokich and Gramont regimens with raltitrexed.…”

Section: Discussionmentioning

confidence: 99%

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

et al. 2004

View full text Add to dashboard Cite

To evaluate the efficacy and toxicity of irinotecan (CPT-11) in combination with raltitrexed as first-line treatment of advanced colorectal cancer (CRC). A total of 91 previously untreated patients with advanced CRC and measurable disease were enrolled in this phase II study. The median age was 62 years (range 31 -77); male/female 54/37; ECOG performance status was 0 in 50 patients (55%), one in 39 (43%) and two in two (2%). Treatment consisted of CPT-11 350 mg m À2 in a 30-min intravenous infusion on day 1, followed after 30 min by a 15-min infusion of raltitrexed 3 mg m À2 . Measurements of efficacy included the following: response rate, time to disease progression and overall survival. Of the 83 evaluable patients valuable to objective response, there were five complete responses (6%) and 23 partial responses (28%), for an overall response rate of 34% (95% CI: 25.9 -46.5%). In all, 36 patients (43%) had stable disease, whereas 19 (23%) had a progression. The median time to progression was 11.1 months and the median overall survival was 15.6 months. A total of 487 cycles of chemotherapy were delivered with a median of five per patient. Grade 3 -4 WHO toxicities were as follows: diarrhoea in 13 patients (15%), nausea/vomiting in four (4%), transaminase increase in six (7%), stomatitis in two (2%), febrile neutropenia in three (3%), anaemia in five (6%) and asthenia in three (3%). The combination CPT-11 -raltitrexed is an effective, well-tolerated and convenient regimen as front-line treatment of advanced CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Groener (1999) An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer 144 Groener 144 reports on an economic evaluation of raltitrexed versus 5-FU/FA in patients with ACRC. The economic perspective of the analysis was not stated; however, the inclusion of indirect costs suggests that the analysis was undertaken using a Dutch societal viewpoint.…”

Section: Economic Evidence For Raltitrexedmentioning

confidence: 99%

“…Groener 144 suggests that the unit costs of chemotherapy and its administration are the main cost drivers in the analysis. However, the author acknowledges that the setting of the trial may not reflect current practice patterns and that other 5-FU regimens should be included in economic evaluations.…”

Section: Economic Evidence For Raltitrexedmentioning

confidence: 99%

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

Hind¹,

Tappenden²,

Tumur³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender. Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour. Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but ...

show abstract

“…Biochemical analysis, in vitro and in vivo, animal and human studies along with phase I-phase II human clinical trials with pilot phase III clinical trials have shown that oral GLN is a safe and effective strategy to prevent and treat mucositis, stomatitis and cachexia [2][3][4][5][6]8,11,12,[15][16][17][18][20][21][22]25,26,[29][30][31][32][33][34]38,39 (M. M. Schubert, unpublished data, 2004). Concerns about GLN being preferentially used by the cancer cells, giving a tumorprotective effect, have been addressed in the research.…”

Section: Resultsmentioning

confidence: 99%

L-Glutamine Use in the Treatment and Prevention of Mucositis and Cachexia: A Naturopathic Perspective

Noé

2009

Integr Cancer Ther

View full text Add to dashboard Cite

Abstractl-Glutamine (l-GLN) is considered a nonessential amino acid that has a variety of applications in naturopathic medicine. It has been postulated that in the critically ill patient, GLN becomes an essential amino acid for recovery, restoration, and repair at a cellular level. Mucositis is an intestinal mucosal damage of the gastrointestinal tract-mouth, throat, stomach, intestines, rectum, and anus-that is caused directly by chemotherapies and radiotherapies. Cancer cachexia is a significant biochemical event, which is characterized by weight loss, fatigue, and indicative of depletion of skeletal muscle GLN-a hypercatabolic state. There has been some question as to the use of GLN in this patient population because of its role as a preferred energy source not only for enterocytes and lymphocytes but for malignant cells as well. This article will address the questions of safety, efficacy, dosing, and toxicity of GLN used as an integrative therapeutic in ongoing integrative cancer treatment.

show abstract

An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer

Cited by 13 publications

References 1 publication

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

L-Glutamine Use in the Treatment and Prevention of Mucositis and Cachexia: A Naturopathic Perspective

Contact Info

Product

Resources

About